What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical evidence from the QuANTUM-First trial indicates that quizartinib improves overall survival compared to placebo, with a hazard ratio of 0.78 (95% CI 0.62 to 0.98). However, the lack of direct comparison with midostaurin and the uncertainties surrounding indirect comparisons limit the strength of the evidence. Thus, while there is moderate benefit, it is not compelling enough to warrant a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for quizartinib are within the acceptable range of £20,000 per QALY gained, as noted by the committee. The economic model, despite some uncertainties, suggests that quizartinib is a defensible option in terms of cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
The document does not provide specific data on HRQoL improvements associated with quizartinib. While there are indications that patients would welcome a new treatment option, the absence of validated tools showing significant improvements in quality of life leads to a rating of minimal impact.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Quizartinib has a very good safety profile, with mostly mild or moderate adverse events reported. The document indicates that the adverse effects are manageable, which supports a strong rating for safety.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparator, midostaurin, was not directly tested against quizartinib, leading to reliance on indirect comparisons. While midostaurin is the most relevant comparator, the lack of direct evidence introduces uncertainty.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population for quizartinib is broadly representative of the intended patient population with FLT3-ITD-positive AML. However, there are some limitations regarding age and other demographic factors that could affect generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Quizartinib can be integrated into existing treatment pathways with minor adjustments, as it is used in combination with standard chemotherapy. This indicates a manageable integration process.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of quizartinib is considered manageable, especially with the commercial arrangement providing a discount. This suggests that the resource implications are justifiable.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
While the evidence from the QuANTUM-First trial is robust, the reliance on indirect comparisons and the uncertainties surrounding them introduce some concerns about the overall robustness of the evidence.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty regarding the indirect treatment comparisons and the overall survival benefits of quizartinib. The committee noted that many results were not statistically significant, which raises concerns about broader impacts.
